Hjelmqvist Lars, Lindberg Charlotte, Kanulf Pär, Dahlgren Henrik, Johansson Ingrid, Siewert Annica
St. Erik's Eye Hospital, Karolinska Institutet, Polhemsgatan 50, 11282 Stockholm, Sweden.
J Ophthalmol. 2011;2011:405724. doi: 10.1155/2011/405724. Epub 2011 Nov 28.
The Swedish Lucentis Quality Registry is a 12-month, open-label, observational, prospective, and retrospective study of ranibizumab administration for wet AMD. Visual acuity (VA) was measured with Snellen or ETDRS chart in 370 patients (66.8% women; age range 46-93 years). In total, a mean of 4.7 ± 1.6 injections per patient (range 1-10) was given to month 12. Mean VA score was 58.3 ± 12.2 letters before treatment, 63.3 ± 12.5 after 3 injections (Δ4.9 ± 10.1 letters from baseline), and 59.3 ± 16.2 at 12 months (Δ1.0 ± 13.6). VA score from baseline to month 12 was stable in 74.4% of patients, improved by 15 letters/3 lines or more in 14.7%, and decreased by ≥15 letters/3 lines in 10.9% of patients. With a mean of 4.7 ranibizumab injections per patient per year, mean VA was stabilised but not increased. To maintain the initial gain seen after the first three injections, an average of 1.8 ± 1.5 additional injections does not appear to be adequate.
瑞典雷珠单抗质量登记研究是一项为期12个月的开放标签、观察性、前瞻性和回顾性研究，旨在观察雷珠单抗治疗湿性年龄相关性黄斑变性（wet AMD）的效果。使用斯内伦视力表或ETDRS视力表对370例患者（66.8%为女性；年龄范围46 - 93岁）进行视力（VA）测量。截至第12个月，每位患者平均接受4.7±1.6次注射（范围为1 - 10次）。治疗前平均视力得分为58.3±12.2字母，3次注射后为63.3±12.5（较基线增加4.9±10.1字母），12个月时为59.3±16.2（较基线增加1.0±13.6字母）。从基线到第12个月，74.4%的患者视力得分稳定，14.7%的患者视力提高了15字母/3行或更多，10.9%的患者视力下降了≥15字母/3行。每位患者每年平均注射4.7次雷珠单抗，平均视力虽稳定但未提高。为维持首次三次注射后出现的初始视力改善，平均额外注射1.8±1.5次似乎并不足够。
